microRNAs Help in Battle for Healthy Cattle

In UK dairy herds, up to a third of cows are affected by disease or reproductive failure and need to be removed before the end of their productive life. This incurs significant costs to farmers and raises serious animal welfare issues.

A procedure to identify early on cows that are likely to have problems later in life would be extremely beneficial for the dairy industry and would have the potential to significantly decrease animal suffering.

A study by scientists at The Roslin Institute and Scotland's Rural College (SRUC) showed that the blood levels of certain microRNAs change dramatically during early life in cows and, importantly, that some microRNAs are closely associated with the incidence of diseases such as lameness and mastitis, as well as with milk production in mature cows.

MicroRNAs are small molecules produced by all body tissues, which play important regulatory roles in animals and plants. MicroRNA levels can be readily quantified in blood using standard laboratory procedures and can be used to assess changes in the function of specific body tissues, a feature that is already being exploited for disease diagnosis in humans.

"As we have already shown in previous studies, these results show that microRNAs may be very useful as diagnostic tools in dairy cows and potentially other livestock species. Specifically, we think that microRNAs could allow for selection early on of the most promising animals in a herd in order to maximise productivity and animal wellbeing," said Dr Xavier Donadeu, one of the authors of the study at The Roslin Institute.

This work has been supported by SRUC funds awarded to Professor Georgios Banos and Dr Xavier Donadeu. The results are published in the journal "Scientific Reports".

This article has been republished from materials provided by the University of Edinburgh. Note: material may have been edited for length and content. For further information, please contact the cited source.

Writing in the journal Cell Chemical Biology, Scripps Research chemist Matthew Disney, PhD, and colleagues describe a new compound that blocks the most common genetic cause of both familial ALS and frontotemporal dementia.

Three new strains of hepatitis C have been found circulating in the general population in sub-Saharan Africa, suggesting that certain antiviral drugs currently used in the West may not be as effective against the new strains.